Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drugging the undruggable.

John P Mayer1, Richard D Dimarchi

  • 1Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. mayer_john_p@lilly.com

Chemistry & Biology
|August 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Publisher Correction: GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice.

Nature·2026
Same author

Semaglutide, at a dose that produces modest weight loss, induces mild suppression of bone remodeling in healthy control rats and those with chronic kidney disease.

Bone·2026
Same author

GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice.

Nature·2026
Same author

GIPR:GCGR co-agonism restores normal weight in obese rodents.

Molecular metabolism·2026
Same author

A High-Potency Protein That Normalizes Body Weight in DIO Mice through Triple Agonism at FGF21, GLP1, and GIP Receptors.

Biochemistry·2026
Same author

Discovery and characterization of canvuparatide, a once-weekly parathyroid hormone analog for the treatment of hypoparathyroidism.

Molecular metabolism·2026
Same journal

The Hedgehog Pathway Effector Smoothened Exhibits Signaling Competency in the Absence of Ciliary Accumulation.

Chemistry & biology·2017
Same journal

DIVERSE System: De Novo Creation of Peptide Tags for Non-enzymatic Covalent Labeling by In Vitro Evolution for Protein Imaging Inside Living Cells.

Chemistry & biology·2015
Same journal

Differential Regulation of Specific Sphingolipids in Colon Cancer Cells during Staurosporine-Induced Apoptosis.

Chemistry & biology·2015
Same journal

Synthetic Peptides as cGMP-Independent Activators of cGMP-Dependent Protein Kinase Iα.

Chemistry & biology·2015
Same journal

Unraveling the B. pseudomallei Heptokinase WcbL: From Structure to Drug Discovery.

Chemistry & biology·2015
Same journal

Vitamin C as Cancer Destroyer, Investigating Sulfhydration, and the Variability in CFTR Interactome.

Chemistry & biology·2015
See all related articles

Researchers developed a new method to create modified peptides that bind strongly and specifically to the Fyn protein's SH3 domain, a key part of the Src kinase family.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • Src kinases, including Fyn, are crucial in cellular signaling pathways.
  • SH3 domains are important protein interaction modules involved in various cellular processes.
  • Targeting specific kinase domains is a key strategy in drug discovery.

Discussion:

  • The study presents an iterative synthesis and selection strategy for peptide ligand discovery.
  • This approach allows for the identification of modified peptides with tailored binding properties.
  • The identified ligands exhibit high affinity and selectivity for the Fyn SH3 domain.

Key Insights:

  • A novel method for generating high-affinity, selective peptide ligands was successfully developed.
  • The identified peptide ligands are potent binders to the SH3 domain of Fyn kinase.

Related Experiment Videos

  • This work demonstrates the utility of iterative selection in discovering specific protein-protein interaction inhibitors.

    • Outlook:

    • The developed methodology can be applied to discover ligands for other kinase targets.
    • These findings may pave the way for novel therapeutic strategies targeting Src family kinases.
    • Further optimization of these peptide ligands could lead to drug candidates for diseases involving Fyn kinase dysregulation.